Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 30, 2020 - Issue 7
Submit an article Journal homepage
331
Views
8
CrossRef citations to date
0
Altmetric
Patent Evaluation

Bispecific anti-PD-1/LAG-3 antibodies for treatment of advanced or metastatic solid tumors: a patent evaluation of US2018326054

Jorge Cebadaa Facultad De Medicina, Benemérita Universidad Autónoma De Puebla, Puebla, Puebla, MexicoView further author information
,
Amira Floresb Instituto De Fisiología, Benemerita Universidad Autónoma De Puebla, Puebla, Puebla, MexicoView further author information
,
Cindy Bandalac Departamento De Neurociencias, Instituto Nacional De Rehabilitación, Ciudad De México, Mexico;d Escuela Superior De Medicina, Instituto Politécnico Naciona, Ciudad De México, MexicoORCID Iconhttps://orcid.org/0000-0002-7414-2621View further author information
ORCID Icon,
Ian Lizaliturri-Florese Lab De Modelado Molecular Y Diseño De Fármacos. Escuela Superior De Medicina, Instituto Politécnico Nacional, Ciudad De México, MexicoView further author information
,
Nemesio Villa-Ruanof Dirección De Innovación Y Transferencia De Conocimiento, Benemérita Universidad Autónoma De Puebla, Puebla, MexicoView further author information
&
Martin Perez-Santosf Dirección De Innovación Y Transferencia De Conocimiento, Benemérita Universidad Autónoma De Puebla, Puebla, MexicoCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-5074-2000View further author information
ORCID Icon
Pages 487-494 | Received 02 Mar 2020, Accepted 06 May 2020, Published online: 20 May 2020

Citations (8)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Marlena Surowka, Wolfgang Schaefer & Christian Klein. (2021) Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins. mAbs 13:1.
Read now

Articles from other publishers (7)

Rongyang Li, Jianhao Qiu, Zhan Zhang, Chenghao Qu, Zhanpeng Tang, Wenhao Yu, Yu Tian & Hui Tian. (2023) Prognostic significance of Lymphocyte-activation gene 3 (LAG3) in patients with solid tumors: a systematic review, meta-analysis and pan-cancer analysis. Cancer Cell International 23:1.
Crossref
Yunong Li, Mingyi Ju, Yuxi Miao, Lin Zhao, Lijuan Xing & Minjie Wei. (2023) Advancement of anti‐LAG ‐3 in cancer therapy . The FASEB Journal 37:11.
Crossref
Keywan Mortezaee & Jamal Majidpoor. (2023) Reinstating immunogenicity using bispecific anti-checkpoint/agent inhibitors. Biomedicine & Pharmacotherapy 162, pages 114621.
Crossref
Anna Kuzevanova, Natalya Apanovich, Danzan Mansorunov, Alexandra Korotaeva & Alexander Karpukhin. (2022) The Features of Checkpoint Receptor—Ligand Interaction in Cancer and the Therapeutic Effectiveness of Their Inhibition. Biomedicines 10:9, pages 2081.
Crossref
Xue Cui, Min Peng & Honglei Chen. (2022) The Emerging Role of Lymphocyte Activation Gene 3 in the Cancer Immunotherapy. Oncologie 24:4, pages 665-678.
Crossref
Florentine E. F. Timmer, Bart Geboers, Sanne Nieuwenhuizen, Madelon Dijkstra, Evelien A. C. Schouten, Robbert S. Puijk, Jan J. J. de Vries, M. Petrousjka van den Tol, Anna M. E. Bruynzeel, Mirte M. Streppel, Johanna W. Wilmink, Hans J. van der Vliet, Martijn R. Meijerink, Hester J. Scheffer & Tanja D. de Gruijl. (2021) Pancreatic Cancer and Immunotherapy: A Clinical Overview. Cancers 13:16, pages 4138.
Crossref
Christian Sordo-Bahamonde, Seila Lorenzo-Herrero, A.P. González-Rodríguez & Segundo González. 2021. Successes and Challenges of NK Immunotherapy. Successes and Challenges of NK Immunotherapy 267 304 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.